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Background: Early diagnosis of Acute Osteomyelitis (OM) and Septic Arthritis (SA) is of vital importance to avoid
devastating complications. There is no single laboratory marker which is sensitive and specific in diagnosing these
infections accurately. Total Count, ESR and CRP are not specific as they can also be elevated in non pyogenic
causes of inflammation. Pus Culture and sensitivity is not a true gold standard due to its varied positivity rates
(40 – 70%). Serum Procalcitonin (PCT), at 0.5 ng/ml is found to be an accurate marker for pyogenic infections. The
objectives of this study were to show that PCT is an accurate marker in differentiating Acute Osteomyelitis and
Septic Arthritis from viral and non infective inflammatory bone and joint conditions.
Methods: Patients of all age groups (n = 82) with suspected Acute Osteomyelitis and Septic Arthritis were
prospectively included in this study. All patients were subjected to TC, CRP, PCT, IgM Dengue, IgM Chikungunya, pus
and blood culture and sensitivity. At the end of the study, patients were classified into 3 groups: Group 1 = Confirmed
Pyogenic (n = 27); Group 2 = Presumed Pyogenic (n = 21); Group 3 = Non – infective inflammatory (n = 34).
Results: Group 1 has higher mean PCT levels than Group 2 and 3 (p < 0.05). PCT, at 0.4 ng/ml, was 85.2% sensitive and
87.3% specific in diagnosing Septic Arthritis and Acute Osteomyelitis. In comparison, PCT at conventional cut – off of
0.5 ng/ml is 66.7% sensitive and 91% specific.
Conclusion: Serum Procalcitonin, at a cut – off of 0.4 ng/ml, is a sensitive and specific marker in the diagnosis of Septic
Arthritis and Acute Osteomyelitis.
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Acute bone and joint infections are truly a diagnostic
enigma in the Emergency Department. Management of
these focuses on providing a rapid etiologic diagnosis
since therapies and outcome vary widely depending
upon the cause. Delayed diagnosis and treatment leading
to disabling sequelae are not uncommon. Functional dis-
abilities occur in 25 to 50% of cases and can even be life
threatening in 5 to 15% of cases [1-3]. Total Count (TC),
Erythrocyte Sedimentation Rate (ESR) and C – Reactive
Protein (CRP) are routinely used in the diagnosis of
these infections but no specific laboratory test exists* Correspondence: drkarthik_ortho_jipmer@yahoo.in
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distribution, and reproduction in any mediumwith the exception of isolation of pathogenic organism
from the bone or synovial fluid [4,5]. A positive culture
result has high specificity but even this cannot be con-
sidered as gold standard because it lacks sensitivity (only
40-60%) and the results are available only after 2 to 3
days [2,3]. Despite this fact, culture is being used by
many researchers as positive gold standard and patients
without any clinical evidence plus negative culture as
negative gold standard. The lack of sensitive laboratory
markers or a gold standard investigation for diagnosing
bacterial infections clinically has contributed to the over-
use of antibiotics especially in neonates and elderly
patients where clinical signs could be very subtle. The
concept of providing antibiotics for every suspectedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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issues with antimicrobial resistance.
In this regard, there is a need for a biochemical marker
which shows high sensitivity and specificity in diagnosing
infection and also as a guide for starting antibiotics. There
is now enough evidence to support the role of Procalcitonin
(PCT) as a diagnostic and prognostic marker in infective
conditions with its very high specificity for bacterial infec-
tions [6-9]. On the contrary, there are only very few studies
evaluating its efficacy in Septic Arthritis (SA) and Acute
Osteomyelitis (OM) with varying results [10-14]. Serum
levels of Procalcitonin is very low in healthy individuals
(< 0.1 ng/ml) and increases rapidly in response to bacterial
endotoxin [15,16]. These properties together with a half life
of 22 to 29 hours have made Procalcitonin, a convenient
tool to monitor serious infections and to discriminate
bacterial infections from viral and non infective inflamma-
tory conditions [17,18]. Owing to its high specificity,
Procalcitonin can also be used as a guide for starting antibi-
otics andmonitoring treatment [19,20].
Hence this study was conducted prospectively with the
objectives to show that PCT is an accurate marker in the
diagnosis of Acute Osteomyelitis and Septic Arthritis.
Early treatment can be started which can decrease the
incidence of disabling sequelae.Materials and methods
This study was conducted in the Department of Ortho-
paedics, in a 1200 bedded tertiary health – care centre
from January 2010 to June 2011. We included all cases
of suspected acute (less than 2 weeks) synovitis / arthritis
and osteomyelitis of all age groups with no evidence of
infection elsewhere. We excluded (1) all cases of chronic
arthritis and chronic osteomyelitis; (2) cases where antibi-
otics were given before presenting to us. (3) cases with foci
of infection elsewhere. (4) immunocompromised hosts.
The study was approved by Institute Research council and
Ethics Committee and conducted in accordance to the
standards of Declaration of Helsinki, 1964. Detailed in-
formed consent was obtained from all patients or from
parents and legal guardians included in this study.
All patients were assessed for clinical parameters which
included presence of swelling; joint effusion; tenderness;
local warmth; deformity; range of movement restriction
and presence of septicemic symptoms. Detailed proforma
was used to record patient details and clinical findings.
Plain radiography [Anteroposterior and Lateral views] and
Ultrasound (USG) of the involved bone and joint were
done. Under adequate anesthesia and proper aseptic pre-
cautions, Aspiration was done using 18G needle from the
joint and bone with subperiosteal abscess. In the absence
of subperiosteal abscess, aspirate was obtained by drilling
the bone with 2 mm drill bit under anesthesia. This wasfollowed by definitive surgery in the form of arthrotomy
or incision and drainage (I&D).
Aspirate was immediately processed for the presence
of pus cells, gram staining, culture and sensitivity (C/S).
All patients were subjected to Blood C/S. Culture and
sensitivity was considered as the gold standard in this
study. Laboratory analyses included estimation of ESR, TC,
CRP, Procalcitonin, IgM Dengue and IgM Chikungunya.
ESR was estimated using Wintrobe’s method. CRP was
measured using Nephelometer [BNPROSPEC, Germany].
The cut-off in our laboratory was 3.02 mg/l above which
CRP was considered positive. PCT was determined by
Quantitative Immunoluminetric test [LUMItest, BRAHMS
Diagnostica, Berlin, Germany) by the investigator who
followed the assay manufacturer’s recommendations. The
threshold for PCT detection defined by our laboratory is
0.1 ng/ml. Samples were analyzed for IgM Dengue and IgM
Chikungunya using ELISA technique. Dengue and Chikun-
gunya are the commonest viral infections presenting with
bone and joint symptoms in our region and the only feasible
tests available in our institution. They were performed to
rule out viral etiology for acute bone and joint infective
conditions.
At the end of the study, patients were divided into
three groups: Confirmed Pyogenic group (Group 1),
Presumed Pyogenic group (Group 2) and Non-Infective
inflammatory group (Group 3) based on the above pa-
rameters. In Group 1, there was a high clinical suspicion
of infection and pus was aspirated. Pus and/or blood
culture was positive for bacteria and patients received
full course of antibiotics [2 weeks of sensitive IV antibi-
otics and 6 weeks of oral antibiotics]. This group included
Culture Positive Septic Arthritis (Group 1a) and Culture
Positive Acute Osteomyelitis (Group 1b). In Group 2,
there was clinical suspicion of infection and altered syn-
ovial fluid was aspirated while aspirate / blood culture
remained negative and these patients too were treated
with full course of antibiotics due to clinical suspicion of
infection. This group included culture negative septic
arthritis (Group 2a) and culture negative acute osteomye-
litis (Group 2b). In Group 3, patients had acute symptoms
pertaining to bone and joint but there was no suspicion of
infection clinically (acute synovitis due to rheumatoid
arthritis, juvenile rheumatoid arthritis, gout, trauma, tran-
sient synovitis of hip, sickle cell bone crisis and non-
specific causes). Synovial fluid was aspirated and aspirate
culture remained negative and hence these patients were
not started on any antibiotics (Table 1).
Mean levels of TC, ESR, CRP and PCT were compared
between these groups and sensitivity, specificity and pre-
dictive values of PCT were assessed.
The statistical significance of all parameters (TC, ESR,
CRP and PCT) were analyzed using Independent Students
T test and One Way ANOVA with BonFerroni PostHoc
Table 1 Patient Characteristics n = 82
Parameter Value
Symptom duration (days)* 3 (2–5)
Males / Females 58 / 24
Age (years) ¥ 25.33 (10 days – 86 years)
Group
Confirmed pyogenic (C+SA / C+OM) 27 (19 / 8)
Presumed pyogenic (C-SA / C-OM) 21 (17 / 4)




Transient synovitis of hip 5
Trauma 7
Sickle cell crisis 1
Non – specific synovitisф 7
Blood C / S 3 (11.11%)
Pus C / S (C+SA / C+OM) 27 (19 / 8)
Methicillin Resistant SA 20 (12 / 8)
Staphylococcus aureus 3 (3 / 0)
Coagulase negative SA 1 (1 / 0)
Pseudomonas aeruginosa 1 (1 / 0)
Klebsiella pneumonia 1 (1 / 0)
Streptoccus species 1 (1 / 0)
* values expressed as median; ¥ value expressed as mean; ф Non specific
synovitis = where cause cannot be found; RA Rheumatoid Arthritis,
C+SA culture positive Septic arthritis, C+OM culture positive acute
osteomyelitis, C-SA culture negative Septic Arthritis, C-OM culture negative
acute osteomyelitis, C/S culture & sensitivity, SA Staphylococcus aureus.
Table 2 Mean with SD for all parameters
Parameter Group N Mean S.D P – value
TC Confirmed 27 9311.11 1531.05 0
Presumed 21 8600 1063.01
Non-pyogenic 34 7279.41 1328.65
ESR Confirmed 27 61.85 10.55 0
Presumed 21 51.57 12.96
Non-pyogenic 34 21.53 11.778
CRP Confirmed 27 12.35 5.77 0.014
Presumed 20 11.31 4.56
Non-pyogenic 9 6.44 3.74
PCT Confirmed 27 1.00 0.73 0
Presumed 21 0.53 0.46
Non-pyogenic 34 0.15 0.05
TC Total Count, ESR Erythrocyte Sedimentation Rate, CRP C – Reactive Protein,
PCT Procalcitonin.
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analyzed using SPSS software version 19. Newcombe
method was used to calculate 95% confidence intervals
(CI). p < 0.05 was considered statistically significant.
Results
A total of 106 patients presented with clinical presenta-
tions suggestive of OM and SA. Out of these, 24 patients
were excluded from the study as 11 patients gave a his-
tory of antibiotic administration before presentation and
13 patients had other foci of infection. The study group
included 82 patients of all age groups (Table 1). The
youngest was a 10 days old neonate and the oldest was
86 years of age with the mean age of 25.33 years. 23
patients (28.04%) were less than 5 years of age and 28
patients (34.14%) were above 40 years. Out of 82 pa-
tients, there were 58 males (70.73%) and 24 females
(29.26). Blood culture was positive (11.11%) for MRSA
in three cases, two cases of SA involving Hip joint and
one case of OM of Distal Femur. MRSA was the
commonest organism isolated from pus. It was positivein 74.07% of patients in Group 1; 63.16% in Group 1a
and 100% in Group 1b. Viral analysis for IgM Dengue
and Chikungunya did not yield any positive results.
All data in this study follow Normal type of distribution.
On comparison of mean (Table 2), Group 1 had higher
mean PCT values (1.0005) than group 2 and 3 which is
statistically significant (p = 0.001). On multivariate ana-
lysis, Group 1b has higher mean PCT values (0.8453) than
Group 1a, but not statistically significant (p = 0.76). Group
2a has higher mean PCT levels (0.5594) than Group 2b
with no statistical significance (p = 0.32). Patients with
positive blood culture had higher mean PCT levels (1.68)
but not statistically significant (p = 0.138). Patients who
grew MRSA in the aspirate had statistically significant
(p = 0.01) highermean PCT levels (1.02). Similarly, patients
who had positive X-ray changes [lytic lesions, erosions,
dislocation] and positive ultrasound findings [presence of
moving echoes in joint / subperiosteal abscess] had statisti-
cally significant higher mean PCT levels 0.82 (p = 0.001)
and 1.06 (p = 0.001) respectively.
On analysis of other parameters, the mean TC and
ESR were found to have raised in Group 1 and 2 with
statistical significance (p < 0.05). In contrast, Group 1
had higher CRP levels than Group 2 which is not statis-
tically significant (p = 0.1).
Sensitivity and specificity PCT at various cut – offs is
depicted in Table 3. For Confirmed versus Presumed /
Non – infective groups, at a cut off of 0.5 ng/ml, PCT is
found to be 66.7% sensitive and 91% specific (PPV =
78.2%; NPV = 84.7%) in diagnosing culture positive pyo-
genic infections. But at 0.4 ng/ml, it is 85.2% sensitive
and 87.3% specific (PPV = 76.6%; NPV = 92.3%). Levels
lower than this has high sensitivity but low specificity
and vice versa. So a cut off at which sensitivity and
specificity got balanced was taken in this study. For




Confirmed / presumed Vs
non infective
Confirmed Vs presumed /
infective
Sensitivity % Specificity % Sensitivity % Specificity %
0.1 100 9.1 100 14.7
0.21 96.3 56.4 97.9 91.2
0.27 88.9 67.3 85.4 97.9
0.3 88.9 74.5 77.1 97.9
0.32 88.9 81.8 68.8 97.9
0.34 83.7 83.6 66.7 100
0.4 85.2 87.3 62.5 100
0.45 74.4 90.9 50 100
0.5 66.7 90.9 47.9 100
0.6 55.6 90.9 41.7 100
0.7 51.9 90.9 37.5 100
0.8 51.9 92.7 35.4 100
0.9 48.1 94.5 33.3 100
1 44.4 94.5 31.3 100
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PCT is 47.9% sensitive and 100% specific (PPV = 100%;
NPV = 57.6%) in diagnosing clinically suspected infec-
tion at 0.5 ng/ml while it is 62.5% sensitive and 100%
specific (PPV = 100%; NPV = 65.4%) at 0.4 ng/ml. For
confirmed pyogenic versus non-pyogenic, at a cut – off
of 0.4 ng/ml, PCT is 85.17% sensitive and 100% specific
with PPV and NPV of 100% and 93.8% respectively
(Table 4).
Area Under the Curve (AUC) on plotting Receiver
Operating Curves (ROC) was 0.886 (S.E= 0.04) for Con-
firmed versus Presumed / Non – infective groups while
AUC is 0.976 (S.E = 0.016) for Confirmed / Presumed
versus Non – infective groups (Figure 1).
Discussion
Septic Arthritis and Acute Osteomyelitis are relatively
common entities in day to day orthopedic practice and
in a tertiary referral centre like ours, it is more common.Table 4 Sensitivity, Specificity and Predictive values of PCT a
Groups PCT (ng/ml) Sensitivity % 95
Confirmed Pyogenic vs presumed +
Non – pyogenic
0.5 66.7 (46 – 83.4
0.4 85.2 (66.3 – 95
Confirmed+ Presumed vs non – pyogenic 0.5 47.9 (33.2 – 62
0.4 62.5 (47.4 – 76
Confirmed vs non – pyogenic 0.5 66.67 (46 – 83
0.4 85.19 (66.3 – 95
PCT Procalcitonin, PPV Positive Predictive Value, NPV Negative Predictive Value, CI C
zero value.But the diagnosis of these infections faces the following
problems: inadvertent use of antibiotics by the physician
who first sees the patient before the proper diagnosis is
made; pus culture and sensitivity which is often consid-
ered the gold standard is not a useful gold standard
because of its low positivity rates; absence of a single
laboratory parameter with high specificity and sensitivity;
dubious presentations of these infections in the very
young and the old; hence the search for a realistic la-
boratory marker is essential.
Many of the complications secondary to delayed diag-
nosis have come down in number due to the availability
of powerful antibiotics but on the other hand this has
led to the emergence of anti- microbial resistance due to
its inadvertent and irrational use. This is of serious con-
cern because practically only few drugs are available as
of now to tackle serious infections [21-23]. PCT has
been found to be a promising marker in diagnosing bac-
terial infections with its high specificity. Its usefulness
over markers like TC, ESR and CRP has been described
in several conditions like sepsis, upper respiratory tract
infections, pneumonias, pancreatitis, pyelonephritis, burns
and in various other conditions [18,24,25]. With this back-
ground, this study was conducted with the following
objectives: To show that PCT is an accurate marker for
differentiating OM and SA from viral infections and non
infective inflammatory bone and joint conditions and to
evaluate Sensitivity, Specificity and Predictive values of
Serum Procalcitonin in diagnosing OM and SA.
Pus culture is expected to be positive in 40 to 60% in
patients of SA and OM though it is 100% specific [2,3].
In the present study, pus culture positivity is 56.25%.
Staphylococcus aureus was described as the most common
identifiable causative organism which accounts for more
than 50% of isolated organism in acute hematogenous
osteomyelitis and 30% in septic arthritis. MRSA is the
commonest organism in the present study isolated in
74.07% of cases (63.16% of septic arthritis cases and 100% of
acute osteomyelitis). Serum PCT level less than 0.5 ng/ml is
considered normal [15,17]. However, there is no unanimous
agreement in deciding the cut – off because PCT is an
emerging diagnostic marker and is either undetectable ort 0.5 and 0.4 ng/ml
% CI Specificity % 95% CI PPV % 95% CI NPV % 95% CI LR
) 91 (80 – 97) 78.2 (56 – 92.5 84.7 (73–92.5) 7.33
.8) 87.3 (75.5 – 94.7) 76.6 (57.7 –90.1) 92.3 (81.5 - 98) 6.69
.8) 100 (89.7 – 100) 100 (85.2 -100) 57.6 (44.1 -70.4) *
) 100 (89.7 – 100) 100 (88.4 – 100) 65.4 (60 – 78) *
.4) 100 (91.2 - 100) 100 (87.4 – 100) 86.3 (77.8 – 94.9) *
.8) 100 (90.2 – 100) 100 (88.7 – 100) 93.8 (82.7 - 96.5) *
onfidence Interval, LR Likelihood Ratio, * LR cannot be calculated because of
Figure 1 ROC for PCT.
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et al., [10]; Fottner et al., [11]; Martinot et al., [13] and Faesh
et al., [14] have taken 0.5 ng/ml as cut – off above which it is
considered as a marker of pyogenic infection. However,
study by Hogle et al., [12] has taken 0.25 ng/ml as the cut-
off. This reflects the absence of a general consensus in de-
ciding the cut-off.
In the present study, the sensitivity, specificity, positive
predictive value and negative predictive value of PCT
was assessed at 0.5 ng/ml and 0.4 ng/ml. For confirmed
pyogenic versus presumed / non pyogenic, at 0.4 ng/ml,Figure 2 Scatter diagram plotting the distribution of patients with rePCT is 85.2% sensitive and 87.3% specific in diagnosing
culture positive SA and OM (Figure 2) with PPV and
NPV of 76.6% and 92.3% respectively. The balancing of
sensitivity and specificity is essential for testing any new
diagnostic marker and hence 0.4 ng/ml is taken as the
cut-off in this study. For confirmed / presumed pyogenic
versus non-pyogenic, at a cut – off of 0.4 ng/ml, PCT is
62.5% sensitive and 100% specific in diagnosing clinically
positive infection with PPV and NPV of 100% and 65.4%
respectively. For confirmed pyogenic versus non-pyogenic,
at a cut – off of 0.4 ng/ml, PCT is 85.17% sensitive andspect to PCT cut-offs.
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with PPV and NPV of 100% and 93.8% respectively.
There are only few studies evaluating the efficacy of
PCT in SA and OM. Butbul Aviel et al., [10] in 2005,
have shown that PCT at 0.5 ng/ml was a poorly sensitive
but highly specific marker using a semi quantitative
PCT card test with higher sensitivity for OM than SA.
However, we have not attempted to analyze separately
for SA and OM as PCT as a marker can diagnose only
the presence and severity of infection and is not
influenced by the site of infection. Similarly, studies by
Fottner et al., [11]; Martinot et al., [13] and Sabine
Faesch et al., [14] have shown PCT as a poorly sensitive
marker with high specificity at a cut-off of 0.5 ng/ml.
This could be due to the low sample size as reflected in
all these studies. The study by Hogle et al., [12] has
shown PCT as a highly sensitive marker but low specific
marker at a cut-off of 0.25 ng/ml. The present study has
included 36 patients of SA and 12 patients of OM which
is considerably higher when compared to other studies.
The present study has shown equally high sensitivity and
specificity when compared to other groups. The strengths
of the present study are: Prospective study; the number of
patients with septic arthritis and acute osteomyelitis are
more when compared to other studies; this study has in-
cluded patients of all age groups; the LUMItest [BRAHMS
Diagnostica] used has a very low detection limit of 0.1 ng/
ml. The limitation of our study is that overall sample size
is low but not to extent of affecting statistical analysis. We
have included patients all age groups (10 days old to 86
years). Though this might have an impact on sensitivity
and specificity rates, majority of patients (66%) in our
study were less than 40 years. Through this study, we
would also like to show that adult septic arthritis is not an
uncommon entity, atleast in our parts of the world. Ours
is a tertiary referral hospital catering to different referral
patterns. Though this might have an impact on the result
of this study, it is less likely as we stringently followed our
inclusion criteria. We have included only cases of dengue
and chikungunya as these are the only relevant viral infec-
tions common in our region but these may not be com-
mon in other parts of the world. The present study was
designed to assess the diagnostic value of PCT. Hence
serial PCT measurements which will help us to study its
prognostic significance were not done.Conclusion
The present study has shown that Serum Procalcitonin, at
a cut – off of 0.4 ng/ml, is a sensitive and specific marker
in the diagnosis of Acute Osteomyelitis and Septic Arth-
ritis. This is in comparison to the conventional cut – off of
0.5 ng/ml which is specific but less sensitive. Thus, Serum
Procalcitonin may be used as a new diagnostic marker forinitiation of treatment in the management of Acute Osteo-
myelitis and Septic arthritis.
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